Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27931468 | 0.88 | KDM4E (0.46) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL17148204 | 0.76 | KDM4E (0.41) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL28995116 | 0.76 | KDM4E (0.46) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL28277232 | 0.75 | MAP4K4 (0.50) | LMNAKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL30025532 | 0.75 | ALDH1A1 (0.64) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL27296318 | 0.75 | ALDH1A1 (0.64) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL30343134 | 0.74 | KMT2A (0.53) | ACHELMNAKDM4EPOLBCASP6 | |
| SCHEMBL1770021 | 0.74 | KMT2A (0.53) | ACHELMNAKDM4EPOLBCASP6 | |
| SCHEMBL25757979 | 0.73 | KMT2A (0.64) | ACHENQO2LMNAKDM4EPOLB | |
| SCHEMBL30977150 | 0.73 | LMNA (0.38) | ACHENQO2LMNAKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | claimed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7947701-B2 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | ACHE 3037/4885NQO2 145/4885LMNA 1408/4885 |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | PRDX2, PRDX1, PRDX5 | ACHE 3245/4885NQO2 373/4885LMNA 2822/4885 |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | ACHE 140/4885NQO2 634/4885LMNA 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.